Thermo Fisher Scientific Expects 5.1% Earnings Move, Upgraded to Buy

By EC Assets · Published 14 October 2026

Thermo Fisher Scientific is projected to see a 5.1% price movement following its third-quarter 2026 earnings report. The company plans to release its earnings on October 21. Thermo Fisher Scientific has a market capitalization of $241.1 billion. The company's stock received an upgrade to a Zacks Rank #2 (Buy). This upgrade reflects an upward trend in earnings estimates. Morgan Stanley raised its target for Thermo Fisher Scientific stock to $730.00 on October 13, 2026. Thermo Fisher Scientific reported its second-quarter revenue on July 23, 2026. Revenue increased 10.00 percent to $11.99 billion. The company holds a mission of making the world healthier, cleaner, and safer. In recent developments, Thermo Fisher Scientific’s clinical research business entered a Study Start-Up Agreement with Quantum BioPharma. This agreement implements a Phase 2 trial of Lucid-MS for progressive multiple sclerosis. Thermo Fisher Scientific also launched the Digital CMC Consortium to advance digital Chemistry, Manufacturing, and Controls for biopharma. This initiative unites biopharma companies. Thermo Fisher Scientific and Evosep entered a reseller agreement for Evosep Eno. This agreement allows customers to purchase Evosep Eno directly through Thermo Fisher Scientific. The arrangement aims to create a seamless customer experience and enable tighter integration. This article is intended for informational purposes only. It does not constitute investment advice.